Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21832Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Zipser, R. D. | en |
| dc.contributor.author | Kronborg, I. | en |
| dc.contributor.author | Rector, W. | en |
| dc.contributor.author | Reynolds, T. | en |
| dc.contributor.author | Daskalopoulos, G. | en |
| dc.date.accessioned | 2015-11-24T19:17:59Z | - |
| dc.date.available | 2015-11-24T19:17:59Z | - |
| dc.identifier.issn | 0016-5085 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21832 | - |
| dc.rights | Default Licence | - |
| dc.subject | 6-Ketoprostaglandin F1 alpha/urine | en |
| dc.subject | Acute Kidney Injury/*drug therapy/urine | en |
| dc.subject | Adult | en |
| dc.subject | Creatinine/metabolism | en |
| dc.subject | Dinoprostone | en |
| dc.subject | Drug Evaluation | en |
| dc.subject | Hepatitis, Alcoholic/*drug therapy/urine | en |
| dc.subject | Humans | en |
| dc.subject | Imidazoles/*therapeutic use | en |
| dc.subject | Middle Aged | en |
| dc.subject | Oxidoreductases/*antagonists & inhibitors | en |
| dc.subject | Prostaglandins E/urine | en |
| dc.subject | Syndrome | en |
| dc.subject | Thromboxane B2/urine | en |
| dc.subject | Thromboxane-A Synthase/*antagonists & inhibitors | en |
| dc.subject | Thromboxanes/*biosynthesis | en |
| dc.title | Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/6593268 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1984 | - |
| heal.abstract | Urinary excretion of the vasoconstrictor metabolite thromboxane B2 is increased in some patients with the hepatorenal syndrome. To define the role of thromboxanes in this syndrome and to evaluate a potential treatment for the renal impairment, we administered the thromboxane synthetase inhibitor dazoxiben to 5 patients with alcoholic hepatitis and rapidly progressive renal failure. Dazoxiben 200 mg/day followed by 400 mg/day reduced urinary thromboxane B2 by approximately 50% without altering prostaglandin E2 or 6-keto prostaglandin F1 alpha and without improving creatinine clearance (6 +/- 2 to 6 +/- 3 ml/min). In 3 additional patients, a higher dose of dazoxiben of 600 mg/day reduced thromboxane B2 by approximately 75% without consistent improvement in renal function. Thus, as judged by selective thromboxane inhibition with dazoxiben, thromboxanes are unlikely to be the key renal vasoconstrictor factor in the hepatorenal syndrome. | en |
| heal.journalName | Gastroenterology | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
